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Impact Of Hypertension versus 
Diabetes on Cardiovascular and 
All-cause Mortality in Iranian 
Older Adults: Results of 14 Years of 
Follow-up
Neda Zafari1, Samaneh Asgari1, Mojtaba Lotfaliany1,2, Amirreza Hadaegh1, Fereidoun Azizi3 
 & Farzad Hadaegh1
To evaluate the joint effect of hypertension (HTN) and diabetes (DM) on coronary heart disease (CHD), 
and stroke event, all-cause, and cardiovascular disease (CVD) mortality in Middle Eastern older adults, 
2747 people (1436 women) aged ≥ 50 years, free of CVD at baseline, were categorized into four 
groups (HTN−/DM−, HTN+/DM−, HTN−/DM+, HTN+/DM+). Multivariate Cox proportional hazard 
models were run for different outcomes. To compare the impact of HTN versus DM, HTN+/DM− was 
considered as reference. In a median of 13.9 years, incidence rate of CHD, and stroke event, all-cause 
and CVD mortality in total population were 19.0, 4.7, 13.5, and 6.4 per 1000 person-years, respectively. 
The multivariate sex-adjusted hazard ratios (HRs) of HTN−/DM+ for CHD, stroke, all-cause mortality 
and CVD mortality were 1.19 (confidence interval (CI): 0.9–1.57), 1.07 (CI: 0.63–1.82), 1.62 (CI: 1.2–2.18), 
and 1.28 (CI: 0.83–1.97); the corresponding HRs for HTN+/DM+ were 1.96 (CI: 1.57–2.46), 1.66 (CI: 
1.1–2.52), 2.32 (CI: 1.8–2.98), and 2.6 (CI: 1.85–3.65) respectively. The associations between HTN/
DM status with stroke incidence and all-cause mortality were stronger among men than in women (P 
for interaction <0.05). Compared to HTN+/DM−, HTN−/DM+ increases all-cause mortality by 62%, 
however, they are not considerably different regarding CHD, stroke incidence and CVD mortality.
The world’s population is aging, (1) a trend that is projected to accelerate in the following decades. The number 
of elderlies by 2050 is projected to more than double its number in 2015, getting to around 2.1 billion. Likewise, 
Iran’s elderly population has increased from 7.22% in 2006 to 8.20% in 2011. Having 70.9% of the population in 
the 15–64 years age group, Iran is awaiting a tremendous rise in its elderly population in the coming decades1.
Aging population is at increased risk of developing hypertension (HTN) and type 2 diabetes mellitus (DM)2–4, 
which are two well-known risk factors of cardiovascular disease (CVD)5, the leading cause of death worldwide6. 
On one hand, it has been estimated that in 2015, 7.8 million deaths and 143 million disability adjusted life years 
were related to systolic blood pressures (SBP) ≥ 140 mmHg7. On the other hand, DM is considered a coronary 
heart disease equivalent;8,9 and even among Iranian population the population attributed hazard fraction of 
all-cause mortality for diabetes was greater than the one for prevalent CVD10.
Studies have investigated the joint prognostic effect of hypertension and diabetes on CVD risk among 
American, European and Asian populations11–14. Regarding all-cause mortality, data is scarce14. Moreover, to the 
best of our knowledge, there is no evidence regarding the comparative effect of these risk factors on CVD morbid-
ity and mortality in the older adults among the Middle East population which has the highest burden of CVD risk 
factors and its mortality15. To top it off, none of the available studies directly compared hypertensive non-diabetic 
individuals with diabetic patients who are free of hypertension regarding CVD morbidity and mortality as well 
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as all-cause mortality. Understanding the extent of the association of different combinations of hypertension and 
diabetes status with CVD events as well as all-cause mortality is crucial especially in low middle income countries 
where the burden of both the risk factors and outcomes is high, yet, the resources are constrained.
The aim of the current study is to first evaluate the total and sex-specified joint effect of hypertension and 
diabetes on coronary heart disease (CHD), and stroke event, all-cause, and CVD mortality in older adults in a 
long-term population based cohort study. Second, to compare the impact of hypertension versus diabetes on the 
abovementioned outcomes in this population.
Methods
Study design and sample. The Tehran Lipid and Glucose Study (TLGS), an ongoing prospective popula-
tion-based study being performed on a representative sample of the Tehran population, aims to determine the 
prevalence and incidence of non-communicable diseases and their risk factors. Detailed descriptions of the TLGS 
have been reported elsewhere16. For the current study, 3890 participants, aged ≥ 50 years [3326 people from the 
baseline examination (1999–2001) and 546 new participants recruited from the second phase (2001–2005)], were 
selected. Subjects with prevalent CVD at their baseline examination (N = 501), missing data of baseline variables 
(N = 354) or without any follow-up data after baseline recruitment (N = 288) were excluded; leaving 2747 par-
ticipants who were followed until 20 March 2014. All experiments were performed in accordance with relevant 
guidelines and regulations. All subjects filled a written consent after being informed about the general aspects 
of the work and the study was approved by the Ethical Committee of Research Institute for Endocrine Sciences.
Clinical and laboratory measurements. Using a pretested questionnaire, a trained interviewer collected 
information, which included demographic data, smoking and drug history. Physical activity level was assessed 
with the Lipid Research Clinic (LRC) questionnaire in the first phase of the TLGS. Due to the inexactness of LRC, 
it was substituted by the Modifiable Activity Questionnaire (MAQ) from the 2nd phase. This questionnaire meas-
ures all three forms of activities including leisure time, job, and household activities in the past year16.
Weight was measured, with subjects minimally clothed without shoes, using digital scales (Seca 707: range 
0–150 kg) and recorded to the nearest 1 kg. Height was measured in a standing position without shoes, using a 
tape meter, while shoulders were in normal alignment. Waist circumference (WC) was measured at the umbilical 
level and that of the hip (HC) at the widest girth of the hip over light clothing, using a tape meter, without any 
pressure to body surface. Measurements were recorded to the nearest 1 cm. BMI was calculated as weight (Kg) 
divided by height squared (m2). Waist to hip (WHR) was calculated as WC (cm) divided by HC (cm).
After a 15-minute rest in the sitting position, two measurements of systolic and diastolic blood pressure (SBP 
and DBP) were taken, on the right arm, using a standardized mercury sphygmomanometer (calibrated by the 
Iranian Institute of Standards and Industrial Researches); the mean of the two measurements was considered as 
the participant’s blood pressure.
A blood sample was taken between 7:00 and 9:00 AM from all study participants, after 12 to 14 hours over-
night fasting. All blood analyses were carried out at the TLGS research laboratory on the day of blood collection. 
For all non- pharmacologically treated diabetic participants aged 20 years and above, an oral glucose tolerance 
test with 82.5 g glucose monohydrate solution [equivalent to 75 g anhydrous glucose; Cerestar EP, Spain] was 
performed and a second blood sample was obtained 2 hours after glucose ingestion. Fasting plasma glucose (FPG) 
and 2hour-post-challenge plasma glucose (2h-PCPG) were measured using an enzymatic colorimetric method 
with glucose oxidase; inter- and intra-assay coefficients of variation at baseline and follow-up phases were both 
less than 2.3%.
Serum total cholesterol (TC) was measured using enzymatic calorimetric tests with cholesterol esterase and 
cholesterol oxidase. High density lipoprotein cholesterol (HDL-C) was measured after precipitation of the apo-
lipoprotein B containing lipoproteins with phosphotungistic acid. Analyses were performed using Pars Azmon 
kits (Pars Azmon Inc., Tehran, Iran) and a Selectra 2 auto-analyzer (Vital Scientific, Spankeren, Netherlands). All 
samples were analyzed when internal quality control met the acceptable criteria.
Definition of Terms. Education level was classified in 3 categories: i) those who had studied less than 6 years, 
ii) those who had studied for 6–12 years, and iii) those with more than 12 years of education. Sports or heavy 
physical activity less than three days per week was defined as low physical activity in the first exam of the TLGS 
using Lipid Research Clinic (LRC) questionnaire. In the second exam, low physical activity was defined as less 
than 600 MET (metabolic equivalent of task) per week, using Modifiable Activity Questionnaire (MAQ)17. “Daily 
smoker” was defined as someone who smoked any kind of tobacco at least once a day and “occasional smoker” 
was one who smoked but not every day; both of them were considered as current smoker. Hypercholesterolemia 
was defined as total cholesterol ≥ 5.18 mmol/L or taking lipid lowering medications. In accordance with the defi-
nition provided by the American Diabetes Association, (29) participants were considered to have T2D if they met 
at least one of these criteria: FPG ≥ 7.0 mmol/L, or 2h-PCPG ≥ 11.1 mmol/L or taking anti-diabetic medication. 
According to JNC 7 guideline18, hypertension was defined as SBP ≥ 140 or DBP ≥ 90 mmHg or using antihyper-
tensive medication. Participants were categorized into four distinct groups according to their baseline hyperten-
sion and diabetes status as followed: i) those who were free of both hypertension and diabetes (HTN−/DM−), ii) 
non-diabetic hypertensive individuals (HTN+/DM−), iii) diabetic individuals without hypertension (HTN−/
DM+), iv) diabetic hypertensive individuals (HTN+/DM+).
Statistical methods. Mean (SD) values for continuous and frequencies (%) for categorical variables of the 
baseline characteristics were described. Baseline characteristics were compared between four categories of hyper-
tension and diabetes (HTN−/DM−, HTN+/DM−, HTN−/DM+, HTN+/DM+) using ANOVA or Chi-square 
tests as appropriate among total population and in each gender.
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Multivariate Cox proportional hazard model adjusted for sex (in total population), age, body mass index, 
waist to hip ratio, education level, low physical activity, current smoking, and hypercholesterolemia was used to 
evaluate the associations of different combinations of hypertension and diabetes with incident CHD, and stroke 
events, all-cause and CVD mortality; given HTN−/DM− as the reference. To compare the impact of HTN versus 
DM, analysis was repeated considering the HTN+/DM− group as reference.
The study survival time was the time from entrance to the study to the date of the first related event. The cen-
soring time of an individual was the time from date of entry into the study until lost to follow-up, death or the 
study end (20 March 2014), whichever happened earlier.
The proportionality of the multivariable Cox model was evaluated using Schoenfeld’s global test of residuals 
and all proportionality hypotheses were appropriate. The interactions between gender and different categories 
of blood pressure and diabetes were checked by log–likelihood ratio test, in multivariate analysis for each event 
separately. Since there was statistically significant interaction for all-cause mortality (p-value = 0.03) and stroke 
(p-value = 0.007) analysis was done separately for men and women. However, in order to report comparable 
results with other studies in this field, we also performed the analysis on a pooled sample.
Statistical analyses were performed using Stata version 12.0 (Stata Corp LP, College Station, Texas).
Data availability. The datasets generated during and/or analyzed during the current study are available from 
the corresponding author on reasonable request.
Results
The study population included a total of 2747 (women = 1436) older adults with mean (SD) age of 59.9 (7.4) 
years [men: 61.1 (7.8), women: 58.8 (6.8)], and mean (SD) BMI 27.8 (4.5) kg/m2. The prevalence of hypertension 
and diabetes at baseline examination were 43.68% and 23.3%, respectively. Among total population, the prev-
alence of HTN+/DM−, HTN−/DM+, and HTN+/DM+ were 30.3%, 9.9%, and 13.4%, respectively. All the 
baseline characteristics except low physical activity in total population were significantly different in four cate-
gories. Comparing baseline characteristics between the four categories in men and women revealed a significant 
difference except for low physical activity in both sexes, education level in men and smoking in women (Table 1).
In a median (inter-quartile range) of 13.9 (9.8–14.5) years, incidence rate of CHD, and stroke event, all-cause 
and CVD mortality in total population were 19.0, 4.7, 13.5, and 6.4 per 1000 person years, respectively. Out 
of 1311 men at baseline, 331 and 90 cases developed CHD, stroke, while 268 and 135 died from all-cause and 
CVD. Out of 1436 women at baseline, 252 and 64 cases developed CHD and stroke, while 180 and 78 died from 
all-cause and CVD (Table 2).
As shown in Fig. 1a looking at the multivariate adjusted hazard ratios for CHD event, in the 3 categories of 
participants compared to the reference (HTN−/DM−), it was shown that being HTN+/DM− increased the risk 
for 64% in the total population (59% in men and 78% in women). However, HTN−/DM+ increased the risk for 
96% in the total population (1.8-fold in men and 2.3-fold in women). In HTN+/DM+ individuals, the risk of 
CHD event rose to more than 3-fold [3.23 95% CI (2.54–4.1), 2.65(1.88–3.7), and 4.1(2.9–5.9), in total popula-
tion, men and women, respectively].
Regarding stroke (Fig. 1b), HTN+/DM− almost doubled the risk of stroke in the total population. The risk 
increased to more than 3-fold in men [HR (95% CI):3.5, (1.94–6.27)]. HTN−/DM+ showed the HR (95% CI) of 
2.4 (1.36–4.25) and 3.76 (1.82–7.76) in the total population and men, respectively. HTN+/DM+ in total popula-
tion were associated with HR (95%CI) of 3.73 (2.28–6.11). The HR splurged to 7.5 (3.8–14.7) in men. In women, 
we did not find any risk for different categories of hypertension and diabetes; considering the limited number of 
events in these groups. In fact, the power of the study to detect the HR of 49% for HTN+/DM+ women was 21%.
Multivariate adjusted hazard ratios (95%CI) for CVD mortality (Fig. 1c) in HTN+/DM− participants were 
2.9 (1.97–4.38) in total population, 2.87 (1.8–4.6) in men, and 2.96 (1.4–6.1) in women. HTN−/DM+ had more 
than 3-fold increased risk in the total population as well as in women, while the number reached to 4-fold in men. 
In HTN +/DM+ individuals, the risk rose to 7.6-fold in total population, almost 6-fold in women and 9-fold in 
men.
For all-cause mortality (Fig. 1d) the HR (95%CI) of HTN+/DM− in the total population was 75% (1.36–
2.26); the corresponding value for men and women were 2.1 (1.51–2.9) and 1.3 (0.86–1.9). In HTN−/DM+ 
individuals, the risk increased to 2.8 (2.1–3.9) and 3.6 (2.5–5.2) in total population and men, respectively. HTN+/
DM+ had about 4-fold rise (3.06–5.4) among total population; in men and women, the HRs (95% CI) reached to 
5.4 (3.7–8.0) and 2.7 (1.78–4.1), respectively.
Repeating the same analyses while choosing HTN+/DM− as the reference group showed that those with 
HTN−/DM+ were not significantly at greater risk of CHD, stroke and CVD mortality, however, being in the 
HTN−/DM+ group increased the risk of all-cause mortality for 62% (1.2–2.18) in total population and 72% 
(1.2–2.45) in men. Those with HTN+/DM+ had increased risk for CHD, stroke, all-cause and CVD mortality 
compared to HTN+/DM− individuals (Table 3).
Discussion
Conducted among the Iranian adults aged 50 years or above during a more than a decade follow-up, the current 
study showed that compared to those who were HTN−/DM− at baseline, both hypertension and diabetes either 
alone or accompanied together increased the risk of CHD event, all-cause and CVD mortality both in men and 
women. Stroke incidence was positively associated with hypertension and diabetes (alone or together) in men 
as well as sex-adjusted multivariate models in the total population. Having HTN+/DM− individuals as the ref-
erence group, the all-cause mortality in HTN−/DM+ group was increased for 72% in men and 62% in total 
population.
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HTN (−)/DM (−) HTN (+)/ DM (−) HTN (−)/ DM (+) HTN (+)/ DM (+) P-value
Men (N = 1311)
Age, year 59.8(7.7) 63.0(8.0) 61.38(7.8) 62.3(7.3) <0.001
BMI, kg/m2 25.4(3.8) 26.9(3.8) 26.9(3.9) 28.3(3.7) <0.001
Waist/Hip 0.94(0.07) 0.97(0.06) 0.97(0.07) 1.0(0.06) <0.001
SBP, mm Hg 118.3(11.3) 150.5(17.6) 122.8(11.2) 153.0(22.8) <0.001
DBP, mm Hg 74.5(8.3) 90.1(11.1) 75.3(8.1) 90.0(13.3) <0.001
Hypercholesterolemia, 
n (%) 382(56.7) 204(56.4) 94(65.3) 97(74.0) 0.001
Current smoking, n (%) 185(27.4) 53(14.6) 35(24.3) 21(16.0) <0.001
Education, n (%) 0.64
<6 years 375(55.6) 218(60.2) 83(57.6) 78(59.5)
6–12 years 217(32.2) 113(31.2) 45(31.2) 41(31.3)
≥12 years 82(12.2) 31(8.6) 16(11.1) 12(9.2)
Low physical activity, n (%) 461(68.4) 248(68.5) 97(67.4) 97(74.0) 0.6
Lipid lowering drugs, n (%) 8(1.2) 15(4.1) 11(7.6) 10(7.6) <0.001
Hypertension drug, n (%) — 88(24.3) — 37(28.2) NA
Diabetes drug, n (%) — — 53(36.8) 37(28.2) NA
Women (N = 1436)
Age, year 57.3(6.3) 60.0(7.1) 57.5(5.4) 60.8(6.9) <0.001
BMI, kg/m2 28.25(4.3) 29.7(4.4) 28.6(4.3) 30.5(5.1) <0.001
Waist/Hip 0.88(0.08) 0.9(0.08) 0.92(0.07) 0.94(0.08) <0.001
SBP, mm Hg 118.7(11.3) 148.2(20.1) 122.7(10.3) 151.9(20.4) <0.001
DBP, mm Hg 75.8(7.6) 90.0(11.1) 77.1(6.8) 90.0(11.6) <0.001
Hypercholesterolemia, 
n (%) 489(81.5) 405(86.0) 107(82.9) 213(90.3) 0.01
Current smoking, n (%) 29(4.8) 11(2.3) 5(3.9) 5(2.1) 0.09
Education, n (%) 0.02
<<6 years 486(81.0) 403(85.6) 108(83.7) 215(91.1)
6–12 years 97(16.2) 58(12.3) 20(15.5) 19(8.1)
≥12 years 17(2.8) 10(2.1) 1(0.8) 2(0.8)
Low physical activity, n (%) 427(71.2) 344(73.0) 91(70.5) 181(76.7) 0.4
Lipid lowering drugs, n (%) 39(6.5) 46(9.8) 19(14.7) 42(17.8) <0.001
Hypertension drug, n (%) — 207(43.9) — 126(53.4) NA
Diabetes drug, n (%) — — 62(48.1) 108(45.8) NA
Total population (N = 2747)
Number (%) 1274(46.4) 833(30.3) 273(9.9) 367(13.4)
Female, n (%) 674(52.9) 362(43.5) 144(52.7) 131(35.7) <0.001
Age, year 58.7(7.2) 61.3(7.6) 59.6(7.0) 61.3(7.1) <0.001
BMI, kg/m2 26.7(4.3) 28.5(4.4) 27.7(4.2) 29.7(4.8) <0.001
Waist/Hip 0.91(0.08) 0.93(0.08) 0.95(0.08) 0.96(0.07)
SBP, mm Hg 118.5(11.3) 149.9(19.1) 122.7(10.8) 152.1(21.3) <0.001
DBP, mm Hg 75.1(8.0) 90.0(11.1) 76.1(7.6) 90.0(12.2) <0.001
Hypercholesterolemia, 
n (%) 871(68.4) 609(73.1) 201(73.6) 310(84.5) <0.001
Current smoking, n (%) 214(16.8) 64(7.7) 40(14.7) 26(7.1) <0.001
Education, n (%) <0.001
<6 years 861(67.6) 621(74.5) 191(70.0) 293(79.8)
6–12 years 314(24.6) 171(20.5) 65(23.8) 60(16.3)
≥12 years 99(7.8) 41(4.9) 17(6.2) 14(3.8)
Low physical activity, n (%) 888(69.7) 592(71.1) 188(68.9) 278(75.7) 0.13
Lipid lowering drugs, n (%) 47(3.7) 61(7.3) 30(11.0) 52(14.2) <0.001
Hypertension drug, n (%) — 295(35.4) — 163(44.4) NA
Diabetes drug, n (%) — — 115(42.1) 145(39.5) NA
Table 1. Baseline Characteristics* of the Study Population. Tehran Lipids and Glucose Study (1999–2014). 
*For continuous variables, mean (SD) is reported; P values for differences across four categories of hypertension 
and diabetes were calculated using ANOVA test. For categorical variables, frequency is reported; P values for 
differences across four categories of hypertension and diabetes were calculated using Chi-square test. HTN, 
hypertension; DM, type 2 diabetes mellitus; BMI, body mass index; SBP, Systolic blood pressure, DBP, Diastolic 
blood pressure, NA, not applicable.
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The independent impact of hypertension and diabetes on CHD, stroke, all-cause and CVD mortality in older 
adults has been shown in many studies4,14,19–25. As shown in many studies using HTN−/DM− as reference, we 
illustrated that HTN+/DM+ individuals had the highest risk of developing CHD, and stroke as well as death 
from all-cause and CVD26–28. A large cohort study conducted among Finnish population11,12, showed that those 
with both hypertension and diabetes at baseline examination were at highest risk for incident CHD, stroke and 
their mortalities; furthermore, Kokubu et al. showed the same results regarding CVD events. However, these find-
ings were not obtained among the American population13. We extend the previous studies by showing individuals 
with both risk factors had higher risk for different outcomes compared with hypertensive non-diabetic individu-
als in multivariate sex adjusted analysis. This is important especially due to the fact that incidence of hypertension 
in diabetic patients and diabetes in hypertensive individuals increases with aging26,29.
Importantly, among hypertensive individuals in our study, only 38% consumed antihypertensive drugs at 
baseline examination. Results of a cohort study conducted in northern region of Iran reported that merely17% 
of hypertensive subjects were using antihypertensive medications;30 a number that reached 25% in national sur-
veys31. Regarding diabetic individuals, in the current study, 40% consumed anti-diabetic medications. Similarly, 
previous studies in TLGS population showed that only half of diagnosed diabetic patients used anti-diabetic 
treatment32. Moreover, national surveys estimate that about half of the diabetes cases are undiagnosed33. Hence, 
it might be hypothesized that, the low frequency of antihypertensive and anti-diabetic drugs consumption in our 
population might be attributable to low awareness of the disorders in the population, inertia for initiating treat-
ment and low adherence to treatment regimen34–36. This issue may contribute to the higher risk of CVD morbidity 
and mortality among hypertensive and diabetic individuals37.
To the best of our knowledge, our study is the first to conduct joint effect analysis comparing HTN−/DM+ 
individuals with HTN+/DM− persons. There are few studies conducted among European, American and Asian 
examining different impact of hypertension and diabetes on CVD incidence and mortality11–14, however, all of 
them considered HTN−/DM− participants as the reference group. Moreover, only one study assessed this issue 
regarding all-cause mortality14. We found out that there is no statistically significant difference between HTN−/
DM+ and HTN+/DM− individuals in developing CHD, stroke and CVD mortality, however, the former group 
showed more than 60% higher risk for all-cause death compared to the latter in the total population as well as 
men. In a recent study, Oh et al. argued that in American older adults, compared to diabetes, hypertension has 
a stronger association with all-cause and CVD mortality. Nevertheless, their conclusion might not be appropri-
ate due to the overlapping confidence intervals of HTN−/DM+ and HTN+/DM− groups14. In line with our 
results, in the study published by Hu et al. the HR for CHD incidence in Finnish diabetic men and women who 
were free of hypertension was 2.39 (1.61–3.55) and 5.63 (3.20–9.88), respectively; the corresponding values for 
non-diabetic stage1 hypertensive individuals were 1.25 (1.13–1.39) in men and 1.52 (1.28–1.81) in women; all of 
which had CIs far enough from the former group. Even the risk for diabetes was higher than among non-diabetic 
stage 2 hypertensive women12. Regarding stroke, results were generally the same for stage 1 hypertension11. 
Several reasons could explain our finding; first, diseases such as cancer and autoimmune disorders may induce 
insulin resistance38. Thus, those with such pre-existing conditions may increase the all-cause mortality under the 
name of diabetes. For this issue, when we excluded the event mortality during the first 3 years of follow-up, results 
did not change (data not shown). Hence, the reverse causality was not responsible for the current results. Second, 
diabetes complications may have been considered independent causes of death. A recent meta-analysis proved 
Event
















person years (95% CI)
Men
HTN (−)/DM (−) 132 17.0(14.3–20.2) 18 2.2(1.4–3.4) 31 3.7(2.6–5.3) 77 9.2(7.3–11.5)
HTN (+)/ DM (−) 102 27.3(22.5–33.1) 37 9.0(6.5–12.4) 45 10.6(7.9–11.3) 89 21.1(17.1–25.9)
HTN (−)/ DM (+) 43 31.3(23.2–42.2) 13 8.4(4.9–14.4) 22 14.0(9.2–21.3) 48 30.6(23.1–40.6)
HTN (+)/ DM (+) 54 45.8(35.0–59.7) 22 16.5(10.9–25.1) 37 27.0(19.6–37.2) 54 39.5(30.2–51.5)
Women
HTN (−)/ DM 
(−) 58 8.0(6.2–10.3) 18 2.4(1.5–3.8) 10 1.3(0.7–2.5) 44 5.8(4.3–7.9)
HTN (+)/ DM (−) 83 14.8(11.9–18.4) 25 4.3(2.9–6.3) 30 5.1(3.5–7.2) 59 9.9(7.7–12.8)
HTN (−)/ DM (+) 28 19.4(13.4–28.1) 5 3.2(1.3–7.7) 7 4.4(2.1–9.3) 16 10.2(6.2–16.6)
HTN (+)/ DM (+) 83 35.04(28.6–43.9) 16 6.0(3.7–9.8) 31 11.4(8.1–16.3) 61 22.5(17.5–28.9)
Total Population
HTN (−)/ DM 
(−) 190 12.6(11.0–14.6) 36 2.3(1.6–3.2) 41 2.6(1.9–3.5) 121 7.6(6.4–9.1)
HTN (+)/ DM (−) 185 19.8(17.1–22.9) 62 6.2(4.8–8.0) 75 7.4(5.9–9.3) 148 14.6(12.4–17.1)
HTN (−)/ DM (+) 71 25.21(20.0–31.8) 18 5.8(3.6–9.2) 29 9.2(6.4–13.3) 64 20.4(15.9–26.1)
HTN (+)/ DM (+) 137 38.9(32.9–46.0) 38 9.5(6.9–13.1) 68 16.7(13.1–21.2) 115 28.2(23.5–33.9)
Table 2. Incidence Rates of Coronary Heart Disease and Stroke and Mortality Rates of Cardiovascular Disease 
and All-cause in Four Different Categories of Hypertension and Diabetes. Tehran Lipids and Glucose Study 
(1999–2014). CI, confidence interval; HTN, hypertension; DM, type 2 diabetes mellitus.
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Figure 1. The multivariate adjusted hazard ratio (95% confidence interval) for coronary heart disease and 
stroke incidence, cardiovascular disease and all-cause mortality. Tehran Lipid and Glucose Study (1999–2014). 
Multivariate Cox proportional hazard model adjusted for sex, age, body mass index, waist to hip ratio, 
education level, current smoking, low physical activity, and hypercholesterolemia in 4 different combinations 
of hypertension and diabetes status i.e. HTN−/DM− (as the reference group), HTN+/DM−, HTN−/DM+, 
HTN+/DM+, for 4 different outcomes namely (a) Coronary heart disease incidence, (b) Stroke incidence 
(c) Cardiovascular disease mortality, and (d) All-cause mortality. CHD, coronary heart disease; CVD, 
cardiovascular disease; CI, confidence interval; HTN, hypertension; DM, type 2 diabetes mellitus.
CHD Incidence P-value
Stroke 




HTN+/DM− Reference — Reference — Reference — Reference —
HTN−/DM+ 1.13(0.79–1.62) 0.5 1.08(0.57–2.04) 0.82 1.43(0.85–2.39) 0.18 1.72(1.2–2.45) 0.003
HTN+/DM+ 1.67(1.19–2.34) 0.003 2.14(1.23–3.72) 0.007 3.21(2.03–5.06) <0.001 2.61(1.83–3.71) <0.001
HTN−/DM− 0.63(0.48–0.82) 0.001 0.29(0.16–0.52) <0.001 0.34(0.21–0.56) <0.001 0.48(0.35–0.66) <0.001
Women
HTN+/DM− Reference — Reference — Reference — Reference —
HTN−/DM+ 1.28(0.83–1.97) 0.26 1.07(0.4–2.86) 0.89 1.04(0.45–2.41) 0.92 1.28(0.73–2.26) 0.38
HTN+/DM+ 2.31(1.69–3.15) <0.001 1.28(0.67–2.42) 0.45 1.99(1.20–3.31) 0.008 2.09(1.45–3.01) <0.001
HTN−/DM− 0.56(0.4–0.79) 0.001 0.85(0.45–1.61) 0.63 0.34(0.16–0.70) 0.004 0.77(0.51–1.16) 0.21
Total Population
HTN+/DM− Reference — Reference — Reference — Reference —
HTN−/DM+ 1.19(0.9–1.57) 0.21 1.07(0.63–1.82) 0.8 1.28(0.83–1.97) 0.27 1.62(1.2–2.18) 0.001
HTN+/DM+ 1.96(1.57–2.46) <0.001 1.66(1.1–2.52) 0.017 2.6(1.85–3.65) <0.001 2.32(1.8–2.98) <0.001
HTN−/DM− 0.61(0.49–0.75) <0.001 0.44(0.29–0.68) <0.001 0.34(0.23–0.51) <0.001 0.57(0.44–0.73) <0.001
Table 3. Multivariate Adjusted* Hazard Ratios for Coronary Heart Disease and Stroke Incidence, 
Cardiovascular Disease and All-cause Mortality According to Hypertension and Diabetes Status. Tehran Lipids 
and Glucose Study (1999–2014). *Adjusted for sex (for total population), age, BMI, waist to hip ratio, education 
level, current smoking, low physical activity, and hypercholesterolemia. CHD, coronary heart disease; CVD, 
cardiovascular disease; HTN, hypertension; DM, type 2 diabetes mellitus. Standard errors were reported as 
confidence intervals and P-values.
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that apart from increasing the risk of vascular diseases, diabetes is associated with substantial premature mortality 
from several cancers, infectious diseases, external causes, and intentional self-harm, and degenerative disorders, 
independent of several major risk factors including systolic blood pressure39.
Considering limitations, first, as inherent to any prospective study, the level of risk factors at the baseline 
examination might change during the follow up. Second, the power of the study to detect the HR for stroke inci-
dence in women was low. Third, unfortunately, measurements of HbA1C were not performed for participant of 
TLGS; hence, we could not use HbA1c as a criterion for defining diabetic patients. Finally, the present study was 
carried out among Persian ethnicities, so the present results cannot be directly extrapolated to other populations.
As for the strengths, our study is the first studying the joint effect of hypertension and diabetes in a large repre-
sentative sample of Iranian older adults in a population with reliable follow-up data. We had reasonable number 
of events in the total population which allowed us to evaluate the long term effects of hypertension and diabetes 
on CHD, stroke incidence and all-cause and CVD mortality. Also, we used both FPG and 2h-PCPG as indica-
tors of diabetes status allowing us to have an accurate estimation of incident T2D.Last but not least, considering 
HTN+/DM− participants as the reference group; we evaluated the impact of diabetes versus hypertension on a 
variety of outcomes.
To the best of our knowledge, our study is the first investigating the joint effect of two worldwide common risk 
factors of CVD i.e. hypertension and diabetes considering HTN+/DM− people as the reference group, hence, 
comparing HTN−/DM+ individuals directly with the former group. We showed that the all-cause mortality 
in HTN−/DM+ people in the total population increased for 62%; a number that rose to 72% in men. Further 
studies are needed to figure out the impact of hypertension versus diabetes on CVD events as well as all-cause 
mortality in other ethnicities.
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